The global cancer immunotherapy market is experiencing significant growth, driven by increasing cancer prevalence, advancements in technology, and growing demand for personalized medicine. Cancer immunotherapy, which harnesses the body's immune system to fight cancer, has emerged as a promising treatment option for various types of cancer. Key players in the market are investing heavily in research and development to introduce innovative immunotherapy drugs and therapies. In addition, collaborations between pharmaceutical companies and research institutions contribute to the market's expansion. The market is characterized by intense competition and a strong focus on research and development to bring innovative therapies to market. The market is expected to grow as new immunotherapy drugs are developed and approved for a wide range of cancers, offering new hope for patients worldwide.
The Global Cancer Immunotherapy Market size was valued at USD 83.57 billion in 2023 and is projected to reach USD 231.33 billion by 2031, with a CAGR of 14.5% during the forecast period of 2024 to 2031.
Below are the Top Cancer Immunotherapy Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
GSK plc.
|
GSK plc. (GlaxoSmithKline) is a key player in the cancer immunotherapy market, focusing on developing innovative treatments that harness the body's immune system to fight cancer. The company has a diverse portfolio of immunotherapy drugs, including checkpoint inhibitors, cancer vaccines, and cell therapies. One of GSK's flagship immunotherapy drugs is dostarlimab, a PD-1 inhibitor being developed to treat various cancers, including endometrial cancer. Dostarlimab has shown promising results in clinical trials, demonstrating efficacy in patients with advanced or recurrent solid tumors. GSK is also active in the field of cancer vaccines, with its MAGE-A3 vaccine being developed to treat non-small cell lung cancer. The vaccine works by stimulating the immune system to target cells that express the MAGE-A3 protein, which is commonly found in cancer cells.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In December 2023, GSK plc entered an exclusive license agreement with Hansoh for HS-20093. Hansoh’s HS-20093 builds on GSK’s oncology portfolio of clinical-stage antibody-drug conjugates. This will help the company to strengthen its product portfolio.
|
|
2.
|
Bristol-Myers Squibb Company
|
Bristol Myers Squibb has a strong portfolio of immunotherapy drugs that are revolutionizing cancer treatment. The company's flagship immunotherapy drugs include Opdivo (nivolumab) and Yervoy (ipilimumab), checkpoint inhibitors that unleash the body's immune system to attack cancer cells. Opdivo has been approved for the treatment of various cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma, among others. Yervoy is also approved for the treatment of melanoma and is often used in combination with Opdivo to enhance its effectiveness. It is also actively involved in researching and developing new immunotherapy treatments. The company is exploring the potential of combining checkpoint inhibitors with other cancer therapies, such as targeted therapies and chemotherapy, to improve patient treatment outcomes.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In May 2022, Bristol-Myers Squibb Company announced the approval of Opdivo plus Yervoy as a first line treatment for adult patients by Japan's Ministry of Health, Labour and Welfare. This may help the company to strengthen its product portfolio.
|
|
3.
|
Incyte.
|
Incyte is a significant player in the cancer immunotherapy market, focusing on developing novel therapies that modulate the immune system to treat cancer. The company's lead immunotherapy drug is pembrolizumab (marketed as Keytruda), a PD-1 inhibitor that has been approved for the treatment of various cancers, including melanoma, non-small cell lung cancer, and head and neck squamous cell carcinoma.
In addition, pembrolizumab, Incyte is also developing other immunotherapy drugs, including epacadostat, a novel IDO1 inhibitor that is being investigated in combination with other therapies for treating various cancers. The company is also exploring the potential of other immunotherapy targets, such as TIM-3 and LAG-3, to develop new cancer treatments. Incyte has a strong commitment to research and development in the field of cancer immunotherapy, with a focus on identifying new targets and developing innovative therapies. The company's pipeline includes several promising immunotherapy drugs in various stages of development, with the potential to impact the treatment landscape for cancer patients significantly.
|
INCB99318 (Oral PD-L1) (Pipeline)
|
North America, Middle East and Africa, Europe, South America, Asia-Pacific
|
In December 2018, Innovent Biologics, Inc. (Innovent) and Incyte announced that the companies, through their respective subsidiaries, had entered into a strategic collaboration agreement for three clinical-stage product candidates discovered and developed by Incyte—pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor), and parsaclisib (PI3Kδ inhibitor). Under the terms of the agreement, Innovent paid Incyte US$40 million in cash up front, and Incyte was eligible to receive an additional US$20 million in consideration in connection with the first investigational new drug (IND) application by Innovent in China.
|
|
4.
|
Gilead Sciences, Inc.
|
Gilead Sciences is a notable player in the cancer immunotherapy market, focusing on developing innovative therapies that harness the body's immune system to fight cancer. The company's immunotherapy portfolio includes several drugs that target different aspects of the immune response to cancer.
One of Gilead's key immunotherapy drugs is Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of certain types of non-Hodgkin lymphoma. Yescarta works by genetically modifying a patient's own T-cells to recognize and attack cancer cells. Gilead is also developing other immunotherapy drugs, including magrolimab, a monoclonal antibody that targets the CD47 protein, which is commonly overexpressed on cancer cells. Magrolimab is being investigated in combination with other therapies for the treatment of various cancers, including acute myeloid leukemia and myelodysplastic syndrome.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In December 2023, Gilead Sciences, Inc. announced U.S. FDA has approved a label update for Yescarta (axicabtagene ciloleucel) to include the overall survival (OS) primary analysis from the landmark Phase 3 ZUMA-7 study showing a statistically significant improvement for Yescarta in OS versus standard of care (SOC) as second-line treatment with curative intent for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy.
|
|
5.
|
Merck & Co., Inc.
|
Merck & Co. has a strong focus on developing innovative treatments that harness the body's immune system to fight cancer. The company's flagship immunotherapy drug is pembrolizumab, marketed as Keytruda, a PD-1 inhibitor approved for treating various cancers, including melanoma, non-small cell lung cancer, and head and neck squamous cell carcinoma, among others. Keytruda has been widely adopted as a standard of care in several cancer types due to its efficacy and tolerability profile. Merck has also actively expanded Keytruda's indications through ongoing clinical trials and research collaborations.
|
|
North America, Middle East and Africa, Europe, South America, Asia
|
In January 2022, Merck & Co., Inc. announced that European Commission (EC) approved Keytruda as monotherapy for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. This might help the company to strengthen its product portfolio.
|
Conclusion
The cancer immunotherapy market is a dynamic and rapidly evolving, with several key players driving innovation and advancement in the field. Companies such as Merck & Co., Bristol Myers Squibb, and Gilead Sciences are at the forefront of developing novel therapies that harness the body's immune system to fight cancer. These companies have developed a strong portfolio of immunotherapy drugs, including checkpoint inhibitors, CAR T-cell therapies, and monoclonal antibodies, which have demonstrated significant efficacy in treating various cancers. The market is characterized by intense competition, with companies investing heavily in research and development to bring new and innovative treatments to market. The success of immunotherapy drugs like Keytruda and Yescarta has paved the way for the development of new and improved therapies, offering new hope for patients with cancer.
